美国正在对进口药品和医疗用品征收关税,迫使制药公司迅速建造国内设施,以避免处罚。 The U.S. is imposing tariffs on imported drugs and medical supplies, pushing pharmaceutical companies to build domestic facilities quickly to avoid penalties.

美国正在发起一项第232节的关税调查,调查医疗装置、个人防护设备和消耗品,并列举了在大流行病时期出现脆弱性后与外国供应链有关的国家安全风险。 The U.S. is launching a Section 232 tariff investigation into medical devices, PPE, and consumables, citing national security risks tied to foreign supply chains, following pandemic-era vulnerabilities. 与此同时,主要制药公司在即将到来的10月1日进口药品关税之前,急忙建造国内制造设施,Eli Lilly、GSK、Novartis和AbbVie承诺提供数十亿美元。 Simultaneously, major pharmaceutical companies are rushing to build domestic manufacturing facilities ahead of a looming October 1 tariff on imported drugs, with billions pledged by Eli Lilly, GSK, Novartis, and AbbVie. 总统特朗普(Trump)宣布对品牌药品征收100%的关税, 除非美国设施建设已经开始, 将“建设”定义为开拓性或积极建设, President Trump announced a 100% tariff on branded pharmaceuticals unless construction has begun on U.S. facilities, defining "building" as ground-breaking or active construction, incentivizing rapid onshoring. 该举措旨在加强供应链的复原力,减少对海外生产的依赖,尽管在药物开发中使用人工智能方面的监管不确定性仍然是创新的障碍。 The move aims to strengthen supply chain resilience and reduce reliance on overseas production, though regulatory uncertainty around AI use in drug development remains a barrier to innovation.